|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.68/-0.08
|
企業價值
13.36M
|
資產負債 |
每股賬面淨值
2.05
|
現金流量 |
現金流量率
--
|
損益表 |
收益
2.39M
|
每股收益
0.21
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/03 05:11 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |